Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Exclusion Criteria

• •Diagnosis of AS or any other Inflammatory Arthritis
• •Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)
• •Exposure to more than 1 tumor necrosis factor (TNF)-antagonist or primary failure to TNF antagonist therapy
• •History of or current chronic or recurrent infections
• •Subjects with known Tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent Tuberculosis (LTB)
• •Recent live vaccination
• •Concurrent malignancy or a history of malignancy
• •Class III or IV congestive heart failure - New York Heart Association (NYHA)
• •Demyelinating disease of the central nervous system
• •Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product
• •Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study